MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562024 | Name: Seretide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Seretide is a combination of fluticasone and salmeterol that is used as an inhaler formulation to manage the symptoms of asthma and chronic obstructive pulmonary disease (COPD).

Chemical Structure

Seretide
CAS#136112-01-1

Theoretical Analysis

MedKoo Cat#: 562024

Name: Seretide

CAS#: 136112-01-1

Chemical Formula: C50H68F3NO9S

Exact Mass: 0.0000

Molecular Weight: 916.14

Elemental Analysis: C, 65.55; H, 7.48; F, 6.22; N, 1.53; O, 15.72; S, 3.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Seretide; Fluticasone/Salmeterol; Advair; Adoair;
IUPAC/Chemical Name
(6S,8S,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl propionate compound with 4-(1-hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol (1:1)
InChi Key
YYAZJTUGSQOFHG-IAVNQIGZSA-N
InChi Code
InChI=1S/C25H31F3O5S.C25H37NO4/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4;27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3;3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2/t13-,15+,16+,18+,19+,22+,23+,24?,25+;/m1./s1
SMILES Code
CCC(O[C@]1(C(SCF)=O)[C@H](C)C[C@@]2([H])[C@]3([H])C[C@H](F)C4=CC(C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)=O)=O.OC5=CC=C(C(O)CNCCCCCCOCCCCC6=CC=CC=C6)C=C5CO
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 916.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Farias G, Ganley WJ, Price R, Conti DS, Mangal S, Bielski E, Newman B, Shur J. Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques. Pharm Res. 2024 Oct 7. doi: 10.1007/s11095-024-03776-1. Epub ahead of print. PMID: 39375241. 2: Gerde P, Sjöberg CO, Bäckroos H, Englund J, Wangheim M, Litorp H. Regional lung targeting with a fluticasone/salmeterol aerosol using a bolus breath hold method of the PreciseInhale® system: A first evaluation in humans. Eur J Pharm Sci. 2024 May 1;196:106742. doi: 10.1016/j.ejps.2024.106742. Epub 2024 Mar 7. PMID: 38460609. 3: Fathi M, Moradi N, Yousefi N, Peiravian F, Shobeiri N. Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country. BMC Pulm Med. 2023 Nov 4;23(1):429. doi: 10.1186/s12890-023-02737-5. PMID: 37925396; PMCID: PMC10625700. 4: D'Angelo D, Chierici V, Quarta E, Varacca G, Cavalieri L, Piraino A, Melani AS, Sonvico F, Buttini F. No-shaking and shake-fire delays affect respirable dose for suspension but not solution pMDIs. Int J Pharm. 2023 Jan 25;631:122478. doi: 10.1016/j.ijpharm.2022.122478. Epub 2022 Dec 16. Erratum in: Int J Pharm. 2023 Feb 25;633:122640. doi: 10.1016/j.ijpharm.2023.122640. PMID: 36535456. 5: Alyami MH, Dahmash EZ, Ali DK, Alyami HS, AbdulKarim H, Alsudir SA. Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine. Pharmaceuticals (Basel). 2022 Mar 8;15(3):321. doi: 10.3390/ph15030321. PMID: 35337119; PMCID: PMC8955190. 6: Wing K, Williamson E, Carpenter JR, Wise L, Schneeweiss S, Smeeth L, Quint JK, Douglas I. Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. Health Technol Assess. 2021 Aug;25(51):1-70. doi: 10.3310/hta25510. PMID: 34463610. 7: Malmberg LP, Pelkonen AS, Vartiainen V, Vahteristo M, Lähelmä S, Jõgi R. Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler® dry powder inhaler: a pooled analysis of two randomized controlled trials. J Thorac Dis. 2021 Feb;13(2):621-631. doi: 10.21037/jtd-20-2112. PMID: 33717535; PMCID: PMC7947512. 8: Roche N, Aguilaniu B, Paternotte S, Dallery N. Real-life association between inhaler technique, patient preference and asthma control in patients with uncontrolled asthma switched to budesonide/formoterol DuoResp® Spiromax® combination. J Asthma. 2022 Apr;59(4):765-774. doi: 10.1080/02770903.2021.1875482. Epub 2021 Feb 13. PMID: 33493074. 9: Cheng SL, Ho ML, Lai YF, Wang HC, Hsu JY, Liu SF, Huang MS, Lee CH, Lin CH, Hang LW, Liu YC, Yang KY, Wang JH. Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study. Drug Des Devel Ther. 2020 Dec 8;14:5441-5450. doi: 10.2147/DDDT.S266177. Erratum in: Drug Des Devel Ther. 2021 Feb 12;15:515-516. doi: 10.2147/DDDT.S300704. PMID: 33324041; PMCID: PMC7733383. 10: Ming SWY, Haughney J, Ryan D, Small I, Lavorini F, Papi A, Singh D, Halpin DMG, Hurst JR, Patel S, Ochel M, Kocks J, Carter V, Hardjojo A, Price DB. A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2020 Nov 26;15:3093-3103. doi: 10.2147/COPD.S263745. PMID: 33273812; PMCID: PMC7705280. 11: Ewing P, Oag S, Lundqvist A, Stomilovic S, Stellert I, Antonsson M, Nunes SF, Andersson PU, Tehler U, Sjöberg C, Péterffy A, Gerde P. Airway Epithelial Lining Fluid and Plasma Pharmacokinetics of Inhaled Fluticasone Propionate and Salmeterol Xinafoate in Mechanically Ventilated Pigs. J Aerosol Med Pulm Drug Deliv. 2021 Aug;34(4):231-241. doi: 10.1089/jamp.2020.1637. Epub 2020 Nov 18. PMID: 33216656. 12: Khanal D, Zhang J, Ke WR, Banaszak Holl MM, Chan HK. Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols. Anal Chem. 2020 Jun 16;92(12):8323-8332. doi: 10.1021/acs.analchem.0c00729. Epub 2020 May 22. PMID: 32406232. 13: Janson C, Henderson R, Löfdahl M, Hedberg M, Sharma R, Wilkinson AJK. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020 Jan;75(1):82-84. doi: 10.1136/thoraxjnl-2019-213744. Epub 2019 Nov 7. PMID: 31699805; PMCID: PMC6929707. 14: Ming PW, Singh DL. Fentanyl-Induced Chest Wall Rigidity as a Cause of Acute Respiratory Failure in the Intensive Care Unit. J Med Cases. 2019 Aug;10(8):249-252. doi: 10.14740/jmc3351. Epub 2019 Aug 26. PMID: 34434315; PMCID: PMC8383706. 15: Rowland M, Cavecchi A, Thielmann F, Kulon J, Shur J, Price R. Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI). Pharm Res. 2018 Nov 26;36(1):15. doi: 10.1007/s11095-018-2544-9. PMID: 30478630. 16: Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA. Cost- effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respir Res. 2018 Nov 20;19(1):224. doi: 10.1186/s12931-018-0916-7. Erratum in: Respir Res. 2019 Jan 28;20(1):18. doi: 10.1186/s12931-019-0985-2. PMID: 30458866; PMCID: PMC6245710. 17: Wayne D, Iverson H, Gillespie M, Hellriegel E, Small C. Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems
. Int J Clin Pharmacol Ther. 2019 Jan;57(1):43-54. doi: 10.5414/CP203216. PMID: 30431426. 18: Jõgi R, Lähelmä S, Vahteristo M, Happonen A, Haikarainen J. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial. J Aerosol Med Pulm Drug Deliv. 2019 Apr;32(2):88-98. doi: 10.1089/jamp.2018.1463. Epub 2018 Oct 9. PMID: 30300557; PMCID: PMC6477585. 19: Panahi Y, Ghanei M, Maghsoudi H, Saffar Soflaei S, Sahebkar A. Investigation of the efficacy of generic and brand-name salmeterol/fluticasone combination in the management of asthma: a randomized comparative trial. Acta Biomed. 2018 Jun 7;89(2):186-192. doi: 10.23750/abm.v89i2.5411. PMID: 29957750; PMCID: PMC6179023. 20: Płoszczuk A, Bosheva M, Spooner K, McIver T, Dissanayake S. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial. Ther Adv Respir Dis. 2018 Jan- Dec;12:1753466618777924. doi: 10.1177/1753466618777924. PMID: 29857783; PMCID: PMC5985608.